tiprankstipranks
Trending News
More News >
IGC Pharma (IGC)
:IGC
Advertisement

IGC Pharma (IGC) Price & Analysis

Compare
983 Followers

IGC Stock Chart & Stats

$0.32
>-$0.01(-2.38%)
At close: 4:00 PM EST
$0.32
>-$0.01(-2.38%)

Bulls Say, Bears Say

Bulls Say
Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Bears Say
Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma News

IGC FAQ

What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.25 and its highest was $0.50 in the past 12 months.
    What is IGC Pharma’s market cap?
    IGC Pharma’s market cap is $35.78M.
      When is IGC Pharma’s upcoming earnings report date?
      IGC Pharma’s upcoming earnings report date is Feb 18, 2026 which is in 79 days.
        How were IGC Pharma’s earnings last quarter?
        IGC Pharma released its earnings results on Nov 17, 2025. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
          Is IGC Pharma overvalued?
          According to Wall Street analysts IGC Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does IGC Pharma pay dividends?
            IGC Pharma does not currently pay dividends.
            What is IGC Pharma’s EPS estimate?
            IGC Pharma’s EPS estimate is -0.02.
              How many shares outstanding does IGC Pharma have?
              IGC Pharma has 91,959,114 shares outstanding.
                What happened to IGC Pharma’s price movement after its last earnings report?
                IGC Pharma reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -5.556%.
                  Which hedge fund is a major shareholder of IGC Pharma?
                  Currently, no hedge funds are holding shares in IGC

                  Company Description

                  IGC Pharma

                  IGC Pharma (IGC) is a biopharmaceutical company focused on developing innovative therapies for the treatment of various medical conditions, including neurological disorders and pain management. The company operates within the pharmaceutical sector, leveraging its proprietary technology platform to create cannabinoid-based formulations. IGC's core products include therapeutics that aim to address significant unmet medical needs, particularly in the areas of mental health and chronic pain.

                  IGC Pharma (IGC) Earnings & Revenues

                  IGC Earnings Call

                  Q2 2025
                  0:00 / 0:00
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Pluri
                  Dyadic International
                  Verrica Pharmaceuticals
                  Elutia
                  LAVA Therapeutics

                  Ownership Overview

                  7.73%1.32%0.30%89.87%
                  0.30% Other Institutional Investors
                  89.87% Public Companies and
                  Individual Investors
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis